Paysign, Inc. (PAYS)
NASDAQInformation TechnologySpecialty Business ServicesSnapshot 2026-09-09
$13.03+1.16%
Close 2026-09-09 · 1-day change
NASDAQInformation TechnologySpecialty Business ServicesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Paysign grows revenue about 23% yearly to $108.5M in 2026. Profit margins expand, with gross profit rising from $13.1M to $18.2M in recent quarters. Net income doubled from $1.4M to $5.4M, showing strong profit growth. The company executes well on balanced plasma and pharma revenue growth.
Growth could slow if plasma and pharma revenue do not expand equally. Margin expansion may stall if costs rise. Litigation or regulatory issues could hurt profits.
The price is about 51% below our fair value near $17. Analysts expect 23% revenue growth. Our view aligns with this but sees risk if growth or margins weaken.
Breaks if: Gross profit falls below $15M in next 4 quarters
Continue to improve gross profit and operating margins through mix shift and expense discipline.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a durable compounder with a focus on expanding revenue and margins. The current thesis state is intact, supported by strong recent financial performance despite some volatility in earnings results.
The market seems to have priced in a justified valuation with a low expectations gap. PAYS trades at a premium compared to its peers, reflecting confidence in its long-term growth potential.
Fundamentals are likely to continue improving as management executes on its priorities. However, there is a near-term risk of missing earnings expectations, given the company's recent history of earnings misses.
The thesis hinges on management's ability to maintain guidance and deliver consistent earnings. Additionally, external factors like Federal Reserve interest rate decisions and performance of sector peers will play a significant role.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Paysign reported Q2 2026 earnings that beat estimates. The company raised its full-year outlook following these results. Additionally, the conference highlighted growth in plasma and pharma revenue.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of last 2 quarters. Gross profit margin improved from 61.6% in 2025-Q2 to 63.3% in 2026-Q2, and operating margin rose from 7.5% to 24.8% in the same period. Management's focus on mix shift and expense discipline is reflected in these margin expansions, indicating delivery on this operational priority.
“Mix shift and expense discipline continue to drive gross and operating margin expansion.”
“Revenue, operating margin and net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability.”
Breaks if: Net income falls below $3M in next 4 quarters
Achieve nearly double net income in 2026 compared to 2025 through growth and margin expansion.
Stated in 2 of last 2 quarters. Net income rose from $1.39M in 2025-Q2 to $6.76M in 2026-Q2, a 386.9% increase. Full-year 2026 net income guidance of $13.0M to $16.0M nearly doubles the 2025 expected range of $7.0M to $8.0M. Management is delivering on the goal to double net income over 2025.
“Net income nearly doubling over 2025 as patient affordability scales.”
“Net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift.”
Breaks if: Revenue falls below $100M in FY26
Continue growing plasma and pharmaceutical revenue streams to contribute roughly equally to total revenue.
Stated in 2 of last 2 quarters. Pharma revenue grew 88.9% from $7.75M in 2025-Q2 to $14.65M in 2026-Q2, while plasma revenue grew 21.4% from $10.74M to $13.04M in the same period. Management consistently expects plasma and pharma to contribute roughly equally to revenue, delivering on this strategic growth priority.
“For the full year, we continue to expect plasma and pharma to contribute roughly equally to revenue.”
“For the full year, we continue to expect plasma and pharma to contribute roughly equally to revenue.”
Overall, PAYS presents a strong operational setup with solid management execution, but it must navigate high risks in the near term. Not investment advice.